Kostas Biliouris (Oppenheimer) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Kostas Biliouris's stock ratings?

About 47% of Kostas's ratings were profitable over a one-year hold, with an average return of +8.5% per rating, measured by 13Foresight from historical prices.

Q: How is Kostas ranked?

Kostas Biliouris is ranked #1601 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Kostas Biliouris

OPCO

Kostas Biliouris

Oppenheimer

Wall Street Analyst

★★★☆☆

#1601

on 13Foresight · ranked by our own returns

47%

Success Rate

+8.5%

Average Return

15 of 32 calls profitable · +0.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 47% of Kostas Biliouris's ratings turned a profit when each position was held for 1 year — averaging +8.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

73 Buy 36 Hold 0 Sell

Kostas's Stock Coverage 28 ratings · 2026-06-26

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ALNY Alnylam Pharma	Jun 25, 2026	BUY	Strong Buy +17.4% avg upside 51 analysts	$500.00 70.51% Upside	·
CNTA Centessa Pharmaceuticals	Jun 24, 2026	HOLD	Buy -21.1% avg upside 19 analysts	—	+0.0%
IRD Opus Genetics	Jun 17, 2026	BUY	Strong Buy +178.2% avg upside 24 analysts	$10.00 168.90% Upside	·
DSGN Design Therapeutics	Jun 15, 2026	BUY	Strong Buy +34.3% avg upside 9 analysts	$21.00 56.15% Upside	·
LEGN Legend Biotech	Jun 15, 2026	BUY	Strong Buy +133.3% avg upside 27 analysts	$75.00 163.80% Upside	-15.5%
DTIL Precision BioSciences	Jun 09, 2026	BUY	Strong Buy +250.0% avg upside 12 analysts	$20.00 196.24% Upside	-5.2%
TRDA Entrada Therapeutics Inc	Jun 03, 2026	BUY	Strong Buy +195.1% avg upside 10 analysts	$23.00 221.65% Upside	+3.5%
EVMN Evommune, Inc.	May 15, 2026	BUY	Strong Buy +108.6% avg upside 12 analysts	$50.00 107.17% Upside	+5.6%
PRME Prime Medicine, Inc.	May 12, 2026	BUY	Strong Buy +215.1% avg upside 16 analysts	$11.00 245.97% Upside	-7.3%
SRPT Sarepta Therapeutics	May 07, 2026	BUY	Buy +272.0% avg upside 49 analysts	$37.00 130.99% Upside	-17.0%
TSE:MSCL Satellos Bioscience	Apr 20, 2026	BUY	Strong Buy +232.3% avg upside 6 analysts	$56.95 492.00% Upside	·
PRQR ProQR	Apr 09, 2026	BUY	Strong Buy +645.6% avg upside 18 analysts	$9.00 475.03% Upside	-26.5%
PEPG PepGen Inc.	Mar 31, 2026	BUY	Strong Buy +517.0% avg upside 9 analysts	$15.00 777.23% Upside	-12.4%
KRRO Korro Bio	Mar 13, 2026	BUY	Strong Buy +118.7% avg upside 19 analysts	$22.00 80.77% Upside	-13.7%
BMRN BioMarin Pharmaceutical	Sep 25, 2025	HOLD	Strong Buy +64.8% avg upside 52 analysts	—	+6.2%
MGX Metagenomi, Inc.	Sep 25, 2025	HOLD	Strong Buy +740.1% avg upside 7 analysts	—	-45.6%
FDMT 4D Molecular Therapeutics	Sep 25, 2025	HOLD	Strong Buy +205.5% avg upside 15 analysts	—	+8.7%
SLN Silence Therapeutics	Sep 25, 2025	HOLD	Strong Buy +235.6% avg upside 10 analysts	—	+22.0%
DYN Dyne Therapeutics	Sep 25, 2025	HOLD	Strong Buy +85.4% avg upside 30 analysts	—	+61.6%
JSPR Jasper Therapeutics	Sep 25, 2025	HOLD	Strong Buy +6416.9% avg upside 17 analysts	—	-79.8%
BEAM Beam Therapeutics	Sep 25, 2025	HOLD	Strong Buy +51.2% avg upside 25 analysts	—	+47.9%
BBIO BridgeBio Pharma	Sep 25, 2025	HOLD	Strong Buy +32.1% avg upside 34 analysts	—	+42.8%
NTLA Intellia Therapeutics	Sep 25, 2025	HOLD	Buy +148.2% avg upside 37 analysts	—	-27.1%
RCKT Rocket Pharmaceuticals	Sep 25, 2025	HOLD	Buy +404.1% avg upside 29 analysts	—	-7.2%
IONS Ionis Pharmaceuticals	Sep 25, 2025	HOLD	Strong Buy +8.0% avg upside 43 analysts	—	+25.2%
CRSP Crispr Therapeutics AG	Sep 23, 2025	BUY	Buy +39.2% avg upside 41 analysts	$75.00 39.00% Upside	-9.6%
LENZ LENZ Therapeutics	Jan 29, 2024	HOLD	Buy +325.5% avg upside 17 analysts	—	+159.6%
LGND Ligand Pharma	Jun 16, 2022	BUY	Strong Buy -22.9% avg upside 15 analysts	$77.00 74.04% Downside	+64.8%

🔒 23 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Kostas Biliouris — Frequently Asked Questions

How accurate are Kostas Biliouris's stock ratings?

Based on the calls 13Foresight could measure, about 47% of Kostas's ratings were profitable over a one-year hold, with an average return of +8.5% per rating, or +0.4% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Kostas ranked on 13Foresight?

Kostas Biliouris is currently ranked #1601 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Kostas cover?

Kostas most recently has ratings on ALNY, CNTA, IRD, DSGN, LEGN, DTIL, TRDA, EVMN, PRME, SRPT, TSE:MSCL, PRQR and 16 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!